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Abstract
Objective
To investigate the distribution, design characteristics, 
and dissemination of clinical trials by funding 
organisation and medical specialty.
Design
Cross sectional descriptive analysis.
Data sources
Trial protocol information from clinicaltrials.gov, 
metadata of journal articles in which trial results 
were published (PubMed), and quality metrics of 
associated journals from SCImago Journal and Country 
Rank database.
Selection criteria
All 45 620 clinical trials evaluating small molecule 
therapeutics, biological drugs, adjuvants, and 
vaccines, completed after January 2006 and before 
July 2015, including randomised controlled trials and 
non-randomised studies across all clinical phases.
Results
Industry was more likely than non-profit funders 
to fund large international randomised controlled 
trials, although methodological differences have 
been decreasing with time. Among 27 835 completed 
efficacy trials (phase II-IV), 15 084 (54.2%) had 
disclosed their findings publicly. Industry was more 
likely than non-profit trial funders to disseminate 
trial results (59.3% (10 444/17 627) v 45.3% 
(4555/10 066)), and large drug companies had 
higher disclosure rates than small ones (66.7% 
(7681/11 508) v 45.2% (2763/6119)). Trials funded 
by the National Institutes of Health (NIH) were 
disseminated more often than those of other non-
profit institutions (60.0% (1451/2417) v 40.6% 
(3104/7649)). Results of studies funded by large 
drug companies and NIH were more likely to appear 
on clinicaltrials.gov than were those from non-profit 
funders, which were published mainly as journal 
articles. Trials reporting the use of randomisation 
were more likely than non-randomised studies to be 
published in a journal article (6895/19 711 (34.9%) 
v 1408/7748 (18.2%)), and journal publication rates 
varied across disease areas, ranging from 42% for 
autoimmune diseases to 20% for oncology.
Conclusions
Trial design and dissemination of results vary 
substantially depending on the type and size of 
funding institution as well as the disease area under 
study.
Introduction
Well conducted clinical trials are widely regarded as 
the best source of evidence on the efficacy and safety of 
medical interventions.1 Trials of first in class drugs also 
provide the most rigorous test of causal mechanisms 
in human disease.2 Findings of clinical trials inform 
regulatory approvals of novel drugs, key clinical 
practice decisions, and guidelines and fuel the progress 
of translational medicine.3 4 However, this model relies 
on trial activity being high quality, transparent, and 
discoverable.5 Randomisation, blinding, adequate 
power, and a clinically relevant patient population 
are among the hallmarks of high quality trials.1 5 
In addition, timely reporting of findings, including 
negative and inconclusive results, ensures fulfilment 
of ethical obligations to trial volunteers and avoids 
unnecessary duplication of research or creation of 
biases in the clinical knowledge base.6 7
To improve the visibility and discoverability of 
clinical trials, the US Food and Drug Administration 
(FDA) mandated the registration of interventional 
efficacy trials and public disclosure of their results.8-11 
Seventeen registries store records of clinical studies.12 13 
Clinicaltrials.gov, the oldest and largest of such 
platforms,14 15 serves as both a continually updated 
trial registry and a database of trial results, thus 
offering an opportunity to explore, examine, and 
monitor the clinical research landscape.10 14
Previous studies of clinical research activity used 
registered trial protocols and associated published 
reports to investigate trends in quality, reporting rate, 
and potential for publication bias.14 16-21 However, 
many previous studies relied on time consuming 
manual literature searches, which confined their scope 
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WhAt Is AlreAdy knoWn on thIs topIc
Suboptimal study design and slow dissemination of findings are common among 
registered clinical trials, with almost half of all studies remaining unpublished 
years after completion
A wider range of organisations is now funding clinical trials
Reporting rates and other quality measures may vary by the type of funding 
organisation
WhAt thIs study Adds
Design characteristics (as a marker of methodological quality) vary by funder 
and medical specialty and associate with reporting rates and the likelihood of 
publication in high impact journals
Results of industry funded trials are more likely to be disclosed than those from 
other funders, although small drug companies lag behind “big pharma”
Big pharma and NIH funded studies show high rates of reporting in clinicaltrials.
gov, and trials funded by other academic and non-profit organisations were 
disclosed primarily as journal articles
Result dissemination rate varies by medical specialty, mainly owing to differential 
journal publication rates, ranging from 42% for autoimmune diseases to 20% for 
oncology
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to pivotal randomised controlled trials or research 
funded by major trial sponsors. Large scale analysis 
of associations between a wide range of protocol 
characteristics and result dissemination rates, and the 
differences between large and small organisations, has 
not been previously undertaken. This is important, 
given a reported growth in trials funded by small 
industrial and academic institutions.22-26
To fill this gap, we did the most comprehensive 
analysis to date of all interventional studies of 
small molecule and biological therapies registered 
on clinicaltrials.gov, up to 19 July 2017. We linked 
trial registry entries to the publication of findings 
in journal articles and used descriptive statistics, 
semantic enrichment, and data visualisation methods 
to investigate and illustrate the landscape and 
evolution of registered clinical trials. Specifically, we 
investigated the influence of type of funder and disease 
area on the design and publication rates of trials across 
a wide range of medical journals; changes over time; 
and associations with reported attrition rates in drug 
development. To facilitate comparison across diverse 
study characteristics, we designed a novel visualisation 
method allowing rapid, intuitive inspection of basic 
trial properties.
Methods
Our large scale, cross sectional analysis and field 
synopsis of the current and historical clinical trial 
landscape used a combination of basic information 
on trial protocols and published trial results. The 
developed data processing and integration workflow 
manipulates and links data from clinicaltrials.gov with 
information about journal articles in which trial results 
were published.
Clinicaltrials.gov data processing and annotation
We downloaded the clinicaltrials.gov database 
as of 19 July 2017—nearly two decades after the 
FDA Modernization Act legislation requiring trial 
registration.8 The primary dataset encompassed 
249 904 studies. We then identified records of all 
pharmaceutical and biopharmaceutical trials, defined 
as clinical studies evaluating small molecule drugs, 
biological drugs, adjuvants, and vaccines.27 To extract 
the relevant subset, we restricted the “study type” field 
to “interventional” and the “intervention type” to either 
“drug” or “biological.” This led to a set of 119 840 
clinical trials with a range of organisations, disease 
areas, and design characteristics (supplementary file 1).
To enable robust aggregate analyses, we processed 
and further annotated the dataset. Firstly, we 
harmonised date formats and age eligibility fields. 
Next, wherever possible, we inferred missing 
categories from available fields as described by 
Califf and colleagues.16 For example, for single arm 
interventional trials with missing allocation and 
blinding type annotations, allocation was assigned as 
“non-randomised” and blinding as “open label.”16 The 
dataset was further enriched with derived variables. 
For example, we derived the trial duration from 
available trial start and primary completion dates, 
mapped trial locations to continents and flagged them 
if they involved emerging markets, and labelled trials 
making use of placebo and/or comparator controls on 
the basis of information from intervention name, arm 
type, trial title, and description field. For instance, if a 
study had an arm of type “placebo comparator” or an 
intervention with a name including words “placebo,” 
“vehicle,” or “sugar pill,” it was annotated as “placebo 
controlled”; similarly, studies with an arm of type 
“active comparator” were classified as “comparator 
controlled” (see supplementary file 2 for details). 
Finally, we annotated each trial with the number of 
outcome measures and eligibility criteria following 
parsing of the unstructured eligibility data field as 
described by Chondrogiannis et al.28
To categorise clinical trials by medical specialty, 
we mapped reported names of disease conditions to 
corresponding medical subject headings (MeSH) terms 
(from both MeSH Thesaurus and MeSH Supplementary 
Concept Records)29 by using a dictionary based named 
entity recognition approach.30 A total of 21 884 distinct 
condition terms were annotated with MeSH identifiers, 
accounting for 86.4% of all disease names from 
88% of the clinical trials (supplementary file 2). The 
mapping enabled normalisation of various synonyms 
to preferred disease names, as well as automatic 
classification of diseases into distinct categories using 
the MeSH hierarchy. To compare our results with 
previously published clinical trial success rates, we 
focused on seven major disease areas investigated 
in the study by Hay et al31: oncology, neurology, and 
autoimmune, endocrine, respiratory, cardiovascular, 
and infectious diseases. We mapped trial conditions 
annotated with MeSH terms to these categories on the 
basis of matching terms from levels 2 and 3 of the MeSH 
term hierarchy; see supplementary file 2 for details on 
MeSH term assignment and disease category mapping.
To categorise studies by type of funder, we first 
extended the agency classification available from 
clinicaltrials.gov. Specifically, we used two main 
categories (industry and non-profit organisations) 
and four sub-categories (big pharma, small 
pharma, National Institutes of Health (NIH), 
and other); the “other” category corresponded 
to universities, hospitals, and other non-profit 
research organisations.32 33 We classified industrial 
organisations as “big pharma” or “small pharma” on 
the basis of their sales in 2016 as well as the overall 
number of registered trials they sponsored. Specifically, 
we classed an industrial organisation as big pharma if 
it featured on the list of 50 companies from the 2016 
Pharmaceutical Executive ranking or if it sponsored 
more than 100 clinical trials34; otherwise, we classified 
it as small pharma (see supplementary file 2). Next, 
we derived the likely source of funding for each trial 
based on the “lead_sponsor” and “collaborators” data 
fields, using a previously described method extended 
to include the distinction between big and small 
commercial organisations.16 Briefly, if NIH was listed 
either as the lead sponsor of a trial or a collaborator, 
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we classified the study as NIH funded. If NIH was not 
involved, but either the lead sponsor or a collaborator 
was from industry, we classified the study as funded 
by either big pharma if it included any big pharma 
organisation or otherwise as small pharma. Remaining 
studies were assigned “other” as the funding source.
Establishing links between trial registry records and 
published results
We linked the trial registry records to the disclosed 
results, either deposited directly on clinicaltrials.gov 
or published as a journal article, to establish whether 
the results of a particular trial had been disseminated. 
We implemented the approach described by Powell-
Smith and Goldacre to identify eligible trials that 
should have publicly disclosed results.20 These were 
studies concluded after January 2006 and by July 
2015 (to allow sufficient time for publication of 
results of studies that had not filed an application 
to delay submission of the results (based on the 
“first_received_results_disposition_date” field in the 
registry).20 We included studies from all organisations 
(even minor institutions) regardless of how many trials 
they funded. The selection process led to a dataset 
of 45 620 studies, including 27 835 efficacy trials 
(phase II-IV), summarised by the flow diagram in 
supplementary file 1.
For each eligible trial, we used two methods to 
search for published results. Firstly, we searched for 
structured reports submitted directly to the results 
database of clinicaltrials.gov (based on the “clinical_
results” field). Next, we queried the PubMed database 
with NCT numbers of eligible trials, using an approach 
that involves searching for the NCT number in the title, 
abstract, and “secondary source ID” field of PubMed 
indexed articles.20 35 36 To exclude study protocols, 
commentaries, and other non-relevant publication 
types, we used the broad “therapy” filter—a standard 
validated PubMed search filter for clinical queries37—as 
well as simple keyword matching for “study protocol” 
in publication titles.20 In addition, we excluded articles 
published before trial completion.
We then determined the proportion of publicly 
disseminated trial reports for the studies covered by 
mandate for submission of results (efficacy trials: 
phase II-IV), as well as for all completed drug trials 
including those not covered by the FDA Amendment 
Act (phase 0-I trials and studies with phase set to 
“n/a”).9 In addition to result dissemination rate, we 
calculated the dissemination lag for individual studies 
to determine the proportion of reports disclosed within 
the required 12 months after completion of a trial. 
We defined dissemination lag as time between study 
completion and first public disclosure of the results 
(whether through submission to clinicaltrials.gov or 
publication in a journal).
Categorising scientific journals
To investigate the relation between characteristics 
of published trials and quality metrics of scientific 
journals, we classified journals as high or low impact 
based on journal metrics information from SCImago 
Journal and Country Rank, a publicly available 
resource that includes journal quality indicators 
developed from the information contained in the 
Scopus database (www.scimagojr.com). Specifically, 
we classified a journal as high impact if its 2016 
H-index was larger than 400 and as low impact if its 
H-index was below 50.
Statistical analysis and data visualisation
We examined the study protocol data for 15 
characteristics available from clinicaltrials.gov 
and from our derived annotations. These were 
randomisation, interventional study design (for 
example, parallel assignment, sequential assignment, 
or crossover studies), masking (open label, single 
blinded, double blinded studies), enrolment (total 
number of participants in completed studies or 
estimated number of participants for ongoing studies), 
arm types (placebo or active comparator), duration, 
number of outcomes (clinical endpoints), number of 
eligibility criteria, study phase, funding source, disease 
category, countries, number of locations, publication 
of results, and reported use of data monitoring 
committees. Further explanation and definitions of 
trial properties are available in supplementary file 2.
On the basis of these criteria characteristics, we 
examined the methodological quality of trials funded 
by different types of organisations and compared 
studies published in higher and lower impact journals 
and reported on clinicaltrials.gov. In addition, we 
analysed trial dissemination rates across funding 
categories and disease areas and compared them with 
clinical success rates reported previously.31
We used descriptive statistics and data visualisation 
methods to characterise trial categories. We report 
frequencies and percentages for categorical data and 
use medians and interquartile ranges for continuous 
variables. To visualise multiple features of clinical trial 
design, we used radar plots with each axis showing 
the fraction of trials with a different property, such 
as reported use of randomisation, blinding, or active 
comparators. We converted three continuous variables 
to binary categories: we classified trials as “small” if 
they enrolled fewer than 100 participants, as “short” if 
they lasted less than 365 days, and as “multi-country” 
if trial recruitment centres were in more than one 
country. Further details are available in supplementary 
tables. To facilitate comparisons between several radar 
plots, we always standardised the order and length of 
axes. We used Python for all data analysis tasks (scikit-
learn, pandas, scipy, and numpy libraries), working 
with geographical data (geonamescache, geopy, and 
Basemap libraries), as well as for data processing 
and visualisation (matplotlib, Basemap, and seaborn 
libraries).
Patient involvement
Patients were not involved in any aspect of the study 
design or conduct or in the development of the 
research question. The study is an analysis of existing 
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publicly available data, so there was no active patient 
recruitment for data collection.
results
Overview of clinical trial activity by funder type
To date, 119 840 drug trials have been registered 
with clinicaltrials.gov. As illustrated by figure 1 (left), 
the distribution of trials funded by different types of 
organisations has changed over time. In particular, 
the proportion of studies funded by organisations 
other than industry or NIH has increased—mainly 
universities, hospitals, and other academic and non-
profit agencies, classified here as “other.” Overall, 
these institutions funded 36% (43 431) of all registered 
pharmaceutical trials, followed by big pharma with 
31% (36 912), and small pharma with 21% (25 216) 
of studies. NIH funded 11% (13 426) of registered 
pharmaceutical trials (fig 1, right).
Among the 10 main study funders ranked by the 
overall number of trials, two belonged to the NIH 
category (National Cancer Institute leading with 
7219 trials) and eight to the big pharma category 
(GlaxoSmithKline at the top with 3171 trials). Of 4914 
small pharma organisations, 3615 (73.6%) had fewer 
than five trials, and 2119 (43.1%) funded only one 
study. Similarly, among the 6468 funders classified as 
“other,” 5124 (79.2%) had fewer than five trials, and 
3630 (56.1%) funded only one study.
The approach outlined in the Methods section 
identified 45 620 clinical trials in our dataset that 
should also have available published results. The 
remaining analysis in the Results section focuses on 
this subset of studies.
Trial design characteristics
The dataset included various types of study designs 
from large randomised clinical trials to small 
single site studies, many of which lacked controls 
(supplementary file 2). Comparative analysis showed 
that methodological characteristics of trials varied 
substantially across clinical phases (fig 2, left), 
disease areas (fig 2, right), and funding source (fig 
3). The next section will focus on a comparative 
analysis by funder type, and a detailed overview of 
differences across phases and diseases is available in 
supplementary file 2.
Industrial organisations were more likely to fund 
large international trials and more often reported 
the use of randomisation, controls, and blinding, 
compared with non-industrial funders. Although 
differences were evident across all clinical phases 
(supplementary file 2), the largest variability was 
observed for phase II trials, illustrated by figure 3. 
For instance, 4956 (68.5%) of all 7236 phase II trials 
funded by industry were randomised (compared with 
39.4% (661/1677) of studies funded by NIH and 
50.6% (1283/2535) funded by other institutions). 
Studies with industrial funding were also substantially 
larger (median 80 patients compared with 43 and 48, 
respectively) and more likely to include international 
locations (31.3% (n=2265) for industry versus 11.0% 
(184) for NIH and 4.0% (101) for others). Despite 
larger enrolment size, industry funded studies were on 
average shorter than trials by other funders (median 
547 days compared with 1431 days for NIH and 941 
for others). Non-industrial funders were more likely 
to report the use of data monitoring committees: 702 
(41.9%) of trials with NIH funding and 1219 (48.1%) 
of studies funded by other organisations involved data 
monitoring committees compared with 1935 (26.7%) 
of trials funded by industry. Design characteristics did 
not differ substantially between trials funded by big 
and small pharma (supplementary file 2).
Trial design changed substantially over time, with 
the trends most evident in phase II. As shown in figure 
4, the methodological differences between industry 
and non-industrial funders have generally decreased 
over time. Although a higher proportion of industry 
led studies reported the use of randomisation overall, 





































































Number of trials over time
All drug trials registered on clinicaltrials.gov
Overall distribution of trial funding source
All drug trials registered on clinicaltrials.gov
Fig 1 | Funding source distribution for all trials registered with clinicaltrials.gov. Left: trends in funding source distribution for all drug trials 
conducted after 1 Jan 1997 until 19 July 2017 (based on the start_date data field). Right: overall funding source distribution for all registered drug 
studies. NIH=National Institutes of Health
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by non-profit organisations in phase II has recently 
increased (fig 4). Notably, the use of blinding is still 
much lower in non-commercial than commercial trials. 
Additional analysis showed that the average numbers 
of trial eligibility criteria and outcome measures have 
increased over time, leading to a greater number of 
procedures performed in an average study, and hence 
to an increase in complexity of trials (supplementary 
file 2).
Dissemination of trial results and characteristics of 
published trials
Of the 45 620 completed trials, 27 835 were efficacy 
studies in phases II-IV covered by the mandate for 
results publication (supplementary file 1). Of these, only 
15 084 (54.2%) have disclosed their results publicly. 
Consistent with previously reported trends,38 39 
dissemination rates were lower for earlier clinical 
phases (not covered by the publication mandate), as 
only 23.4% (2504/10 691) of trials in phases 0-I had 
publicly disclosed results (supplementary file 2).
Detailed analysis of phase II-IV trials showed that 
only 3822 (25.2%) of published studies disclosed their 
results within the required period of 12 months after 
completion. The median time to first public reporting, 
whether through direct submission to clinicaltrials.
gov or publication in a journal, was 18.6 months. 
Dissemination lag was smaller for results submitted 
to clinicaltrials.gov (median 15.3 months) than for 
results published in a journal (median 23.9 months).
Of 27 835 phase II-IV studies, 10 554 (37.9%) 
disclosed the results through structured submission 
to clinicaltrials.gov, 8338 (29.95%) through a journal 
article, and 3808 (13.7%) through both resources. 
Scientific articles were published in 1454 titles of 
diverse nature and varying impact factor. These ranged 
from prestigious general medical journals (BMJ, JAMA, 
Lancet, New England Journal of Medicine) to narrower 
focus, specialist journals with no impact information 
available.
Journal publication status depended on study 
design. Trials reporting the use of randomisation were 
more likely to be published than non-randomised 
studies (35.0% (6895/19 711) v 18.2% (1408/7748)), 
and large trials enrolling more than 100 participants 

















Fig 3 | Phase II trial properties by funding source. Radar 
chart illustrates differences between three groups of 
trials (represented by coloured polygons) with respect 
to 15 trial protocol characteristics (individual radial 
axes). Axis shows fraction of trials with given property, 
such as reported use of randomisation, blinding, or data 
monitoring committees (DMC). Detailed statistics across 
four funding categories and remaining clinical phases 



































Fig 2 | Trial design properties. Each radar chart illustrates differences between three groups of trials (represented by coloured polygons) with 
respect to 15 trial protocol characteristics (individual radial axes). Each axis shows fraction of trials with given property, such as reported use 
of randomisation, blinding, or data monitoring committees (DMC). Left: trial characteristics by clinical phase. Right: characteristics of phase II 
treatment oriented trials for three representative diseases. Profile of glioblastoma (with many small non-randomised studies) is typical of oncology 
trials; see supplementary file 2. NIH=National Institutes of Health
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than 100 participants (39.3% (5541/14 106) v 20.5% 
(2753/13 422)).
In general, studies whose results were disclosed 
in the form of a scientific publication were more 
likely to follow the ideal randomised clinical trial 
design paradigms than were those whose results were 
submitted to clinicaltrials.gov only (fig 5). A similar 
trend was observed for trials with results published 
in higher versus lower impact journals. For instance, 
89.6% (1009/1126) of trials published in journals 
with an H-index above 400 reported the use of 
randomisation, compared with 79.0% (1223/1548) 
of trials published in journals with an H index below 
50 and 60.7% (5459/8999) of trials whose results 
were submitted to clinicaltrials.gov only (fig 5 and 
supplementary file 3). The characteristics of trials 
disclosed solely through submission to clinicaltrials.gov 
did not substantially differ from those not disseminated 
in any form (supplementary files 2 and 3).
Trial dissemination rates across funder types
Trial dissemination rates varied among the different 
funding source categories (table 2 in supplementary 
file 2). In general, industry funded studies were more 
likely to disclose results than were non-commercial 
trials (59.3% (10 444/17 627) v 45.3% (4555/10 066)) 
of all completed phase II-IV studies). They were also 
more likely to report the results on clinicaltrials.gov 
(45.6% (8041) v 24.4% (2457)) and had a shorter time 
to reporting (median 14.5 v 18.0 months). Notably, 
only a small difference was observed for journal 
publication rates (31.0% (5460) v 28.1% (2827)). 
Additional analysis showed substantial differences 
across more granular funder categories (fig 6, top left). 
Among non-profit funders, a gap existed between NIH 
funded studies and those funded by other academic 


























































































Fig 4 | Changes in clinical trial design over time. Plots compare characteristics of all phase II trials (regardless of completion status) divided into four 


















Fig 5 | Changes in clinical trial design over time. Plots 
compare characteristics of all phase II trials (regardless 
of completion status) divided into four temporal 
subsets based on their starting year. Additional results 
are available in supplementary file 2. NIH=National 
Institutes of Health
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and 40.6% (3104/7649) of trials being disclosed from 
the two categories, respectively. Similarly, among the 
industry funded clinical trials, big pharma had a higher 
result dissemination rate than small pharma (66.7% 
(7681/11 508) v 45.2% (2763/6119) of studies); see 
table 2 in supplementary file 2 for details.
In addition to overall reporting rates, the analysis also 
highlighted differences in the nature and timing of 
dissemination of results across trial funding sources 
(fig 6). Big pharma had the highest dissemination 
rate, both in terms of clinicaltrials.gov submission 
(53.2% (6122/11 508) of studies) and journal publi-
cations (34.8% (4005)). By contrast, funders classi-
fied as “other” showed the lowest percentage of trials 
published on clinicaltrials.gov (15.9% (1214/7649)). 
Organisations from this category disclosed trial results 
primarily through journal articles (29.1% (2229) of 
all studies) and were the only funder type with fewer 
trials reported through clinicaltrials.gov submission 
than through journal publication. The time to report-
ing trials at clinicaltrials.gov was fastest for industry 
funded trials and slowest for studies funded by organ-
isations classed as “other;” publication lag for journal 
articles showed a reverse profile (see figure 6, bottom 
left and right, and table 2 in supplementary file 2 for 
detailed statistics).
Analysis of the fraction of trials with results disclosed 
within the required 12 months after completion 
showed that dissemination rates have been steadily 
growing with time, with the largest increase observed 
after 2007, when the FDA Amendments Act came into 
effect.9 Further analysis showed that the observed 
growth was largely driven by increased timely reporting 
on clinicaltrials.gov, most evident for studies funded 
by big pharma and NIH (supplementary file 2).
Trial dissemination rates across disease categories
Disease areas with highest dissemination of results 
were autoimmune diseases and infectious diseases, 
whereas neurology and oncology showed the lowest 
dissemination rates (fig 7). As shown on the left 
side of figure 7, these differences were largely driven 
by differential trends in journal publication, with 
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Fig 6 | Trial results dissemination rates by trial funding category. Top left: trial dissemination rates by funder type: overall dissemination rate, journal 
publications, and submission of structured results to clinicaltrials.gov. Top right: time to first results dissemination (whether through submission 
to clinicaltrials.gov results database or publication in journal article). Vertical line indicates 12 month deadline for reporting mandated by Food and 
Drug Administration Amendments Act. Bottom left: time to results reporting on clinicaltrials.gov. Bottom right: time to journal article publication. 
NIH=National Institutes of Health
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on clinicaltrials.gov. Oncology in particular had 
consistently the lowest journal publication rate across 
all clinical phases and funder categories.
The two disease categories with the highest fraction 
of published trials (autoimmune and infectious 
diseases) were also previously associated with highest 
likelihood of new drug approval (12.7% (n=549) and 
16.7% (537), respectively).31 Similarly, the two disease 
areas showing the lowest proportion of published trials 
also had the lowest drug approval rates: neurology 
(likelihood of 9.4%; n=986) and oncology (6.7%; 
n=1083).31 Cardiovascular diseases had a relatively 
high publication rate but a low clinical trial success 
rate, with only 7.1% (n=426) of tested compounds 
eventually approved for marketing.31
discussion
This analysis, enabled by automated data driven 
analytics, provided several important insights on the 
scope of research activity and the design, visibility, 
and reporting of clinical trials of drugs. Trial activity 
has grown and diversified, with a more diverse range 
of profit and non-profit organisations undertaking 
clinical research across a wide range of disease areas, 
and the analysis highlighted potentially important 
differences in the quality and dissemination of trials.
In terms of trial design, industry funded studies 
tended to use more robust methods than studies 
funded by non-profit institutions, although the 
methodological differences have been decreasing 
with time. Rates of dissemination of results varied 
substantially depending on the disease area as well 
as the type and size of funding institution. In general, 
the results of industry funded trials were more likely to 
be disclosed compared with non-commercial studies, 
although small drug companies lagged behind “big 
pharma.” Similarly, trials with NIH funding more often 
disclosed their results than did those funded by other 
academic and non-profit organisations. Although 
overall dissemination rates have improved with time, 
the trend was largely driven by increased reporting of 
results on clinicaltrials.gov for big pharma and NIH 
funded studies. By contrast, the results of trials funded 
by other academic and non-profit organisations were 
primarily published as journal articles and were rarely 
submitted to clinicaltrials.gov. Finally, differences in 
dissemination rates across medical specialties were 
mainly due to differential journal publication rates 
ranging from 42% for autoimmune diseases to 20% for 
oncology.
Strengths and limitations of study
One of the major strengths of this work is the larger 
volume of clinical trials data and the greater depth 
and detail of the analysis compared with previous 
studies in this area. Many factors were analysed for the 
first time in the context of both quality of trial design 
and transparency of research. These included the 
distinction between big pharma and smaller industrial 
organisations, analysis of publication trends across 
distinct medical specialties, and differences between 
trials whose results were disseminated through 
submission to clinicaltrials.gov and publication 
in higher or lower impact journals. In addition, 
the study provided a novel method for visualising 
the characteristics of trials, which enables a rapid 
assimilation of similarities and differences across a 
variety of factors.
The study had several limitations related to the 
underlying dataset and the methods used to annotate 
and integrate the data. Firstly, it was limited to the 
clinicaltrials.gov database and hence did not include 
unregistered studies. However, given that registration 
of trials has been widely accepted and enforced 
by regulators and journal editors,8 12 most of the 
influential studies will probably have been captured 
in the analysis.40 Additional limitations were due 
to data quality factors such as missing or incorrect 
entries, ambiguous terminology, and lack of semantic 
standardisation.14 16 Many trials were annotated as 
placebo or comparator controlled on the basis of 
information mined from their unstructured titles 
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Fig 6 | Trial results dissemination rates and funding 
source distribution across seven medical specialties. 
Top: for each specialty, plot shows fraction of 
completed phase II-IV trials whose results were publicly 
disseminated, either as journal article or through 
direct submission to clinicaltrials.gov results database. 
Bottom: funding source distribution by medical specialty. 
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structured “arm type” field was often missing. Although 
we analysed a subset of annotations manually, our 
automatic workflow might still have misclassified some 
trials. In addition, owing to the non-standardised free 
text format of the data, we used only a simple count 
of eligibility criteria and outcome measures as an 
imperfect proxy for assessing the complexity of trials 
and the homogeneity of enrolled population.
Finally, our method for linking registry records 
to associated publications relied on the presence 
of a registry identifier (NCT number) in the text or 
metadata of a journal article. Its absence from a trial 
publication would lead to misclassified publication 
status and, consequently, underestimated publication 
rates. However, owing to the rigorousness of the search 
methods, the publication status is unlikely to have been 
misclassified in a systematic manner—for example, 
depending on study funding source or disease area. 
Hence, although absolute estimates might be affected, 
the comparative analysis based on automated record 
linkage is unlikely to have been biased towards one 
of the categories. Notably, reporting of registration 
numbers is encouraged by medical journals through 
ICMJE and the CONSORT checklist, and it can be argued 
that compliance is part of investigators’ responsibility 
to ensure that their research is transparent and 
discoverable.20 35
Comparison with other studies
In addition to providing novel contributions, our 
analysis further confirmed and extended several 
findings reported previously by others. Notably, larger 
sample size, wide inclusion criteria, and additional 
mappings allowed us to calculate more accurate 
statistics and ask previously unexplored questions 
in an unbiased way. For instance, Bala et al showed 
that trials published in higher impact journals have 
larger enrolment size on the basis of a sample of 1140 
reports of randomised clinical trials and manual 
searches.41 Our study extended this analysis to the 
entire clinicaltrials.gov registry (not only randomised 
trials) and many additional trial properties beyond 
enrolment size, including reported use of data 
monitoring committees, duration of the studies, and 
number of countries. Other previously reported trends 
confirmed and further examined in this study included 
lower reporting rate observed for earlier clinical phases 
and academic sponsors,38 39 longer dissemination lag 
for journal publications,42 and overall improvements 
in dissemination of results.43
Several previous studies investigated the 
transparency of clinical research by using various 
subsets of clinicaltrials.gov and diverse approaches 
for classifying study results as published,17 20 36-39 44 45 
summarised in detail elsewhere.46 47 General trends 
shown by our study were within estimates reported 
previously, and our estimate of 54% for the overall 
trial dissemination rate was in agreement with 
two recent systematic reviews.46 47 Our study is 
methodologically most similar to the work by Powell-
Smith and Goldacre,20 with one important distinction: 
we did not restrict the analysis to trials sponsored 
by organisations with more than 30 studies, as this 
would exclude small drug companies and research 
centres and bias the results towards large institutions 
that routinely perform or fund clinical research. As a 
consequence, the analysis showed analogous trends 
but slightly lower overall reporting rates compared 
with that study.20
Meaning and implications of study
The higher methodological quality of industry 
funded trials may reflect the available financial 
and organisational resources, as well as better 
infrastructure and expertise in conducting clinical 
trials.48 49 Differential objectives of the industrial and 
non-profit investigators (development of new drugs 
with a view to gaining a licence for market access 
versus mechanistic research and rapid publication 
of novel findings) may also have contributed to the 
observed differences.48 50
The analysis suggests that trials funded by large 
institutions that regularly conduct clinical research 
are more likely to have their results disseminated 
publicly. Although industry led reporting overall, 
large drug companies performed much better than 
smaller organisations, probably because many large 
companies have developed explicit disclosure policies 
in the recent years.51-53 Similarly, NIH has developed 
specific regulations for disseminating the results of the 
studies it funds. The most recent such policy requires 
the publication of all NIH funded trials, including 
(unprecedentedly) phase I safety studies.54 Although 
large trial sponsors seem to actively pursue better 
transparency,38 smaller organisations, particularly those 
in the non-profit sector, were less responsive to the FDA 
Amendments Act publication mandate. Such institutions 
may be less able, or less motivated, to allocate the time 
and resources needed to prepare and submit the results, 
or they may be less familiar with the legislation.38 40
Our study suggests that the FDA mandate for 
dissemination of trial results and the establishment 
of the clinicaltrials.gov results database led to 
improved transparency of clinical research. The time to 
dissemination of results is shorter for clinicaltrials.gov 
than for traditional publication, and the database stores 
the results of many otherwise unpublished studies. 
Lack of journal publications might be explained by the 
reluctance of editors to publish smaller studies based 
on suboptimal design or studies with “negative” or 
non-significant outcomes that are unlikely to influence 
clinical practice.41 55 56 Our analysis showed that 
journal publication varied depending on trial design 
and disease area, with certain medical specialties 
and smaller non-randomised studies more likely to 
be disseminated solely through clinicaltrials.gov. The 
difference was particularly evident for oncology. Only 
a fifth of completed cancer trials were published in a 
journal, perhaps owing to the high prevalence of small 
sample sizes, suboptimal trial designs, and negative 
outcomes in this field.14 31 High rates of dissemination 
on clinicaltrials.gov, including for cancer trials and 
RESEARCH
10 doi: 10.1136/bmj.k2130 | BMJ 2018;361:k2130 | the bmj
small studies, suggests that this resource plays an 
important role in reducing publication bias. Thus, to 
assure better completeness of available evidence, the 
database should be used by clinical and drug discovery 
researchers in addition to literature reviews.
Importantly, automated analyses and methods for 
identification of yet to be published studies could be 
used by regulators and funders of clinical research to 
track trial investigators who failed to disclose the results 
of their studies. Such a technology would be particularly 
useful when coupled with automated notifications and 
additional incentives (or sanctions) for dissemination 
of results. Recently, the concept of automated ongoing 
audit of trial reporting was implemented through an 
online TrialTracker tool that monitors major clinical trial 
sponsors with more than 30 studies.20 Improvements 
to the quality of clinical trial data could facilitate the 
development of robust monitoring systems in the future. 
Firstly, data quality should be taken into account when 
registering new trials and standardised nomenclature 
should be used whenever possible. Ideally, the user 
interface of the clinicaltrials.gov registry itself should 
be designed to encourage and facilitate normalisation. 
In addition, stricter adherence to the CONSORT 
requirement for including the trial registration number 
with each published article would improve the accuracy 
of automated mapping of registry records to associated 
publications.40
In addition to improved monitoring, new regulations 
might be needed to ensure better transparency, and it 
is important that small industrial organisations and 
academic centres are reached by these efforts as well. 
One possible solution was proposed by Anderson 
and colleagues38: journal editors from ICMJE could 
call for submission of results to clinicaltrials.gov as a 
requirement for article publication. Given the dramatic 
increase in trial registration rates that followed 
previous ICMJE policies,57 58 such a call would be likely 
to improve the reporting of ongoing clinical research.38
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